EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Primemd Inc (PRMD) fair value: what the stock is really worth

As of Sep 28, 2026: fair value of Primemd Inc $0.00, price $0.00, upside +0.1%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US74167A1016

PI Primemd Inc logo Thin data Sep 30, 2026

Primemd Inc

PRMD · US

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value $0.0009 · Fairly valued (+0.1%)
!Quality 54/100
!Weak Growth
!Loss over the last twelve months · -117.1% net margin (TTM) · fiscal year 2021 29.9%
✓generates free cash flow
!Trails peers (2/8)
!Narrow moat 18/100
!Evidence only low, so the estimate is less certain
Watch Primemd Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.9500 $0.0002 Fair Value $0.0009 Apr 1994 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 30, 2026.

How to read this chart

60‑month range $0.0002 – $0.9500 · fair‑value band $0.0009 – $0.0009 · the $0.0009 price screens below the $0.0009 fair value. Dashed = 300-day average. As of Sep 30, 2026.

Follow Primemd in your weekly email

Every Wednesday you see whether Primemd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Primemd Inc., together with its subsidiaries, is engaged in the purchase and development of residential and commercial real estate properties in the United States. It also holds interests in oil and gas properties. The company was formerly known as Eagle Exploration Co. and changed its name to Primemd Inc. in June 2021.

Show more

Primemd Inc., together with its subsidiaries, is engaged in the purchase and development of residential and commercial real estate properties in the United States. It also holds interests in oil and gas properties. The company was formerly known as Eagle Exploration Co. and changed its name to Primemd Inc. in June 2021. The company is based in Littleton, Colorado.

Stock analysis

Primemd Inc (PRMD) currently trades at $0.0009, while our model-based Fair Value estimate is $0.0009, so the stock looks roughly fairly valued today (gap 0.1%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $0.0013 per share, and 7 of the 18 models we run sit above the $0.0009 price.

Bear case: the Asset-Based group reads lowest at $0.0001, and 11 of the 18 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0009 (bear) to $0.0009 (bull), the price of $0.0009 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Primemd Inc reported revenue of $10.5M in FY2021 versus $39.1K in FY2004, a compound +39.0%/yr. Reported net income was $3.1M in FY2021.

Key figures

Market cap $20.3K · P/S ratio 0.29 · Net margin 29.9% · Return on equity −6.9% · Return on assets (EBIT) −5.0% · Operating margin −142% · Revenue growth (YoY) −57.8% · Free cash flow $2.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 200% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 0%, PRMD screens richer than that median.

Fair Value models

Bear $0.0009 Fair Value $0.0009 Bull $0.0009
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.0006 $0.0009 $0.0018 74
Growth DCF $0.0005 $0.0010 $0.0018 72
Owner Earnings $0.0006 $0.0013 $0.0026 68
All 18 models by family
DCF Models
FCF DCF $0.0006 $0.0009 $0.0018 74
Owner Earnings $0.0006 $0.0013 $0.0026 68
5Y Revenue Exit $0.0004 $0.0007 $0.0012 67
5Y P/E Exit $0.0007 $0.0014 $0.0024 66
10Y Revenue Exit $0.0004 $0.0008 $0.0012 63
10Y P/E Exit $0.0007 $0.0013 $0.0025 58
Earnings-Based
Graham-Dodd $0.0003 $0.0021 $0.0030 63
Lynch FV $0.0006 $0.0009 $0.0012 61
PEG = 1.0 $0.0006 $0.0009 $0.0012 57
Multiples
P/E Multiple $0.0008 $0.0010 $0.0013 63
P/S Multiple $0.0004 $0.0005 $0.0007 58
P/B Multiple $0.0004 $0.0005 $0.0006 55
EV/Revenue $0.0003 $0.0005 $0.0006 51
Asset-Based
NCAV (Graham) $0.0001 $0.0001 $0.0001 51
Growth DCF
Growth DCF $0.0005 $0.0010 $0.0018 72
Rev-Margin DCF $0.0004 $0.0007 $0.0012 68
Economic Profit
Residual Income $0.0003 $0.0005 $0.0013 61
Growth Earnings
Growth-Adj P/E $0.0009 $0.0013 $0.0016 67

Open the full fair value analysis →

Notify me when PRMD reaches fair value

Put PRMD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 54/100

Of which business quality 63 · Market factors (momentum, volatility) 67

Profitability 89
Margins and returns on capital today
Quality Growth 90
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 23
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 88
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−249.5% (2002) → −158.4% (2007)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch PRMD, get fair value alerts →

Compare Primemd Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside +0.1% · Above median
Profitability
Return on assets −1.8% · Bottom 25%
Net margin (TTM) −117.1% · Bottom 25%
Operating margin (TTM) −142.1% · Bottom 25%
Growth and dividend
Revenue growth −57.8% · Bottom 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/S (TTM) 0.29× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 33
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 31
HEALTH (low debt)0 · sector 89
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €46.15 €34.49 −25%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Primemd Inc · Fair Value
$0.0009 +0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Primemd Inc Fair Value". https://www.fairvalue-calculator.com/stock/PRMD

Frequently asked questions

Is Primemd Inc (PRMD) overvalued or undervalued?
As of Sep 30, 2026, our model estimates a fair value of $0.0009 versus a price of $0.0009, about +0% upside (fairly valued).
What is the fair value of PRMD?
Our model-based fair value for Primemd Inc is $0.0009 (as of Sep 30, 2026), built from audited fundamentals. The current price: $0.0009.
What is the quality score of PRMD?
Primemd Inc has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Primemd Inc (PRMD)?
Our model-based price target is the fair value of $0.0009 (as of Sep 30, 2026) from 18 valuation models. Cautious scenario $0.0009, optimistic scenario $0.0009. It is a calculation from audited fundamentals, not an analyst target.
What is the Primemd Inc stock forecast for 2026?
Our models put fair value at $0.0009, about +0% upside versus a price of $0.0009 (fairly valued). Cautious scenario $0.0009, optimistic scenario $0.0009. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Primemd Inc (PRMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Primemd Inc it is $0.0009 per share (as of Sep 30, 2026), against a price of $0.0009. It is the blended result of 18 valuation models (cash flow, earnings, asset, dividend).
Is Primemd Inc stock overvalued or undervalued in 2026?
As of Sep 30, 2026, PRMD trades below its calculated fair value: price $0.0009, fair value $0.0009, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRMD?
No. The price is what the market pays today ($0.0009); the fair value is what the company's own numbers justify ($0.0009). For Primemd Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Primemd Inc worth?
The market values Primemd Inc at about $20.3K (market capitalisation, as of Sep 30, 2026). Per share that is $0.0009; our models calculate a fair value of $0.0009 per share.
What do the bullish and bearish scenarios say about PRMD?
Our models span a range for Primemd Inc: cautious scenario $0.0009, base $0.0009, optimistic $0.0009 per share (as of Sep 30, 2026, price $0.0009). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Primemd Inc (PRMD)?
Balance-sheet figures for Primemd Inc (as of Sep 30, 2026): return on equity −6.9%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is PRMD from its 52-week high?
Primemd Inc trades at $0.0009, about 18% below its 52-week high of $0.0011 and 200% above the low of $0.0003 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0009 is for.
Which stocks are comparable to Primemd Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Primemd Inc stock attractive at the current price?
The data as of Sep 30, 2026: price $0.0009, calculated fair value $0.0009 (+0%), Quality Score 54/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRMD calculated?
We run Primemd Inc through 18 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0009, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Primemd Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Primemd Inc (PRMD)?
The closing price on Sep 28, 2026 was $0.0009. Our model-based fair value is $0.0009, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Primemd Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0009 to $0.0009), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Primemd Inc

How large is the market capitalisation of Primemd Inc (PRMD)?
The market capitalisation of Primemd Inc is $20.3K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Primemd Inc (PRMD)?
The price-to-sales ratio of Primemd Inc is 0.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Primemd Inc (PRMD)?
The net margin of Primemd Inc is 29.9% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Primemd Inc (PRMD)?
The return on equity (ROE) of Primemd Inc is −6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Primemd Inc (PRMD)?
On an EBIT basis the return on assets of Primemd Inc is −5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Primemd Inc (PRMD)?
The operating margin of Primemd Inc is −142% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Primemd Inc (PRMD)?
Revenue at Primemd Inc is growing −57.8% versus a year earlier (3y avg +484%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Primemd Inc (PRMD) generate?
The free cash flow of Primemd Inc is $2.2M (fiscal year 2021). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Primemd Inc (PRMD) carry?
The net debt of Primemd Inc is $4.5M (fiscal year 2021, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Primemd Inc in the live analysis

One click puts Primemd Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.